Under the agreement, LigoCyte will receive milestone payments on the successful development of drug candidates.
The collaboration includes an opportunity for co-development, co-promotion, and sharing of profits resulting from commercialized products.
CD103 is the unique alphaE-beta7 integrin that has been implicated in the activation, homing and retention of lymphocytes that mediate inflammatory diseases affecting mucosal regions of the intestine, skin, and lungs.
Under terms of the agreement, LigoCyte will receive milestone payments on the successful development of drug candidates. The collaboration includes an opportunity for co-development, co-promotion, and sharing of profits resulting from commercialized products.
Donald Beeman, CEO and chairman of the board for LigoCyte, said: “We are very pleased to be entering into this collaboration with Biogen Idec for the development of our lead anti-inflammatory therapy. This strategic alliance confirms the value of LigoCyte’s immunology expertise.”